🟢 IBRX is trading 9.3% up today on FDA acceptance of ANKTIVA sBLA for bladder cancer

IBRX is trading at $8.48 (+9.28%) following the FDA's acceptance of ImmunityBio’s supplemental Biologics License Application (sBLA) for ANKTIVA.

• The filing seeks to expand ANKTIVA’s indication for use in combination with BCG for patients with BCG-unresponsive non-muscle invasive bladder cancer.
• This regulatory milestone is a significant step toward broadening the product’s addressable market and serves as a key company-specific catalyst.
• Trading volume remains high as the stock extends gains from its previous close of $7.76.